J&J pulls 667,000 Sudafed packs on labeling error

Yet another recall for the Johnson & Johnson tally. This time, we're back to consumer drugs. McNeil Consumer Healthcare is pulling nine lots of Sudafed tablets--667,632 packages, to be exact--because of a labeling error. It's the second recall of a Sudafed product this year and the fourth J&J episode this month.

When McNeil announced the previous Sudafed recall, the company said it had found insufficient cleaning procedures on the production line. "McNeil identified the inadequacies as part of a thorough, proactive quality and process assessment of all McNeil produced products," the company said in a statement.

This latest recall would seem to stem from the same assessment: The culprit was an extra "not" in a sentence about safe Sudafed use. J&J appears to be going over its manufacturing and packaging with a fine-toothed comb.

- see the J&J announcement
- get more from Bloomberg

Suggested Articles

While the failure might be a missed chance at revenue, it shouldn’t hurt Ibrance’s ability to rack up sales in the metastatic setting, one exec says.

Patients receiving Bavencio actually did worse than those who got placebo, increasing the risk of death by 31%.

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.